Immunofluorescence staining for CD248, PD-L1, CD3, and CD8 in tumor sections showed reduced CD248 and PD-L1 expression in both untreated and treated cKO mice, along with greater CD8+ T cell infiltration in the tislelizumab-treated cKO group (Figure 6I). The gene discussed is CD8A; the disease is neoplasm.